INTS
NASD Intensity Therapeutics, Inc.$3.31 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.31, $0.39 below the day’s high of $3.70
- YTD change
- -67.72%
- vs 20-day SMA
- -11.27%
- vs 200-day SMA
- -42.28%
Price ranges
Price & Performance
-2.15 (-39.38%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 98.8% away from all-time highs of $286.00
- INTS is down 68% since the beginning of the year
- INTS is down 57% over the past 12 months
- INTS is down 18% over the past 1 month
- 1% of all INTS investors are betting against INTS
INTS reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +1003.3%.
- Previous minute
- +$0.00
- Last hour
- -$0.05
- Last 5 days
- -3.78%
- vs 8-day SMA
- -5.87%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.